Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

被引:83
|
作者
Ganbaatar, Byambasuren [1 ]
Fukuda, Daiju [2 ]
Shinohara, Masakazu [3 ,4 ]
Yagi, Shusuke [1 ]
Kusunose, Kenya [1 ]
Yamada, Hirotsugu [5 ]
Soeki, Takeshi [1 ]
Hirata, Ken-ichi [6 ]
Sata, Masataka [1 ]
机构
[1] Tokushima Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Cardiodiabet Med, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[5] Tokushima Univ, Dept Community Med Cardiol, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[6] Kobe Univ, Div Cardiovasc Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan
关键词
Atherosclerosis; Inflammation; Endothelial function; SGLT2; inhibitor; Empagliflozin; PERIVASCULAR ADIPOSE-TISSUE; SGLT2; INHIBITOR; MORTALITY; ATHEROSCLEROSIS; PHENOTYPE; DISEASE; ROLES; AGES;
D O I
10.1016/j.ejphar.2020.173040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE(-/-)) mice. Male streptozotocin (STZ) - induced diabetic ApoE(-/-) mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE / mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E-2 and thromboxane B-2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-alpha in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE(-/-) mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Resveratrol improves endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice
    Li, Jinghua
    Zhong, Zhenwei
    Yuan, Jiru
    Chen, Xiaohang
    Huang, Ziyang
    Wu, Zeyu
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2019, 67 : 63 - 71
  • [2] Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice
    d'Uscio, LV
    Baker, TA
    Mantilla, CB
    Smith, L
    Weiler, D
    Sieck, GC
    Katusic, ZS
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (06) : 1017 - 1022
  • [3] Acetylshikonin suppresses atherogenesis by attenuating vascular inflammation in apolipoprotein E-deficient mice
    Cui, Libao
    Yan, Ying
    Zhang, Min
    Wu, Jianfeng
    Tang, Xiangxiang
    Yang, Jie
    Li, Lanlin
    Yao, Ke
    Zou, Wenguang
    Jiang, Chonghui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (03): : 1882 - 1890
  • [4] N-methylnicotinamide protects against endothelial dysfunction and attenuates atherogenesis in apolipoprotein E-deficient mice
    Jiang, Nan
    Wang, Min
    Song, Jiayi
    Liu, Yan
    Chen, Hongen
    Mu, Di
    Xia, Min
    MOLECULAR NUTRITION & FOOD RESEARCH, 2016, 60 (07) : 1625 - 1636
  • [5] Empagliflozin, a SGLT2 inhibitor, attenuates endothelial dysfunction and atherogenesis by inhibiting inflammatory responses in the vasculature and adipose tissue in diabetic apolipoprotein E-deficient
    Ganbaatar, B.
    Fukuda, D.
    Yagi, S.
    Kusunose, K.
    Yamada, H.
    Soeki, T.
    Sata, M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1881 - 1881
  • [6] Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient Mice
    Du, Fen
    Gesang, Quzhen
    Cao, Jia
    Qian, Mei
    Ma, Li
    Wu, Dongfang
    Yu, Hong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (11)
  • [7] Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice
    Aini, Kunduziayi
    Fukuda, Daiju
    Tanaka, Kimie
    Higashikuni, Yasutomi
    Hirata, Yoichiro
    Yagi, Shusuke
    Kusunose, Kenya
    Yamada, Hirotsugu
    Soeki, Takeshi
    Sata, Masataka
    INTERNATIONAL HEART JOURNAL, 2019, 60 (06) : 1421 - 1429
  • [8] Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice
    Maine S Cola
    Agata L Gava
    Silvana S Meyrelles
    Elisardo C Vasquez
    Lipids in Health and Disease, 9
  • [9] Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice
    Cola, Maine S.
    Gava, Agata L.
    Meyrelles, Silvana S.
    Vasquez, Elisardo C.
    LIPIDS IN HEALTH AND DISEASE, 2010, 9
  • [10] Ticagrelor Prevents Endothelial Dysfunction of Aortas in Apolipoprotein E-deficient Mice
    Li, Xiaoyan
    Zhang, Erhong
    Xue, Jiaojie
    Du, Yu
    Xie, Jingwen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (16) : C11 - C11